Daylife Select
A point & click tool to create dynamic content portals. Learn More »
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
The Computerized Speech Lab (CSL) is a speech and signal processing computer workstation (software and hardware) used for research and clinical speech therapy. Full Article
IOWA CITY, IA - AUGUST 11: A syringe of the H1N1 vaccine, developed by CSL of Australia, is held at the University of Iowa Health Center during trial of the vaccine on August 11, 2009 in Iowa City, Iowa.
View Photo »IOWA CITY, IA - AUGUST 11: A syringe of the H1N1 vaccine, developed by CSL of Australia, is held at the University of Iowa Health Center during trial of the vaccine on August 11, 2009 in Iowa City, Iowa.
View Photo »In this Wednesday, July 22, 2009 photo provided by CSL, nurse Luiza Duszynski measures a swine flu vaccine dose at the Royal Adelaide Hospital in Adelaide, Australia.
View Photo »In this Wednesday, July 22, 2009 photo provided by CSL, Holly Pyke, left, receives a swine flu vaccination by nurse Luiza Duszynski as Taralee Seaton looks on in the background at the Royal Adelaide Hospital in Adelaide, Australia.
View Photo »In this Wednesday, July 22, 2009 photo provided by CSL, Taralee Seaton, left, receives a swine flu vaccination by nurse Luiza Duszynski at the Royal Adelaide Hospital in Adelaide, Australia.
View Photo »The BMW Art Car 3.0 CSL, 1976 by Frank Stella is displayed during a preview of the exhibition "BMW Art Car Collection" at the Museum of Contemporary Art (MARCO) in Monterrey, northern Mexico June 4, 2009.
View Photo »The BMW Art Car 3.0 CSL, 1976 by Frank Stella is displayed during a preview of the exhibition "BMW Art Car Collection" at the Museum of Contemporary Art (MARCO) in Monterrey, northern Mexico June 4, 2009.
View Photo »The BMW Art Car 3.0 CSL, 1976 by Frank Stella is displayed during a preview of the exhibition "BMW Art Car Collection" at the Museum of Contemporary Art (MARCO) in Monterrey, northern Mexico June 4, 2009.
View Photo »The BMW Art Car 3.0 CSL, 1976 by Frank Stella is displayed during a preview of the exhibition "BMW Art Car Collection" at the Museum of Contemporary Art (MARCO) in Monterrey, northern Mexico June 4, 2009.
View Photo »Rep. Bart Stupak, D-Mich. , speaks to CSL Biotherapies, Inc.
View Photo »CSL Biotherapies, Inc. President Paul Perreault, left, accompanied by Novartis Vaccines USA President Vas Narasimham, testifies on Capitol Hill in Washington, Wednesday, Nov. 18, 2009, before a joint House Health and Oversight and Investigation subcommittee's hearing on H1N1 Preparedness...
View Photo »From left, CSL Biotherapies, Inc.
View Photo »Czech President Vaclav Klaus (3th L, front) welcomes the (L to R) Chairman of the Czech Senate Premysl Sobotka, Chairman of Czech Parliament Miroslov Vlcek, Czech Prime Minister Jan Fischer, Chairman of the Civic Democratic Party (ODS) Mirek Topolanek, Chairman of the Social Democrats (...
View Photo »IOWA CITY, IA - AUGUST 11: Marisa Grunder, 27 of Wilton, Iowa, speaks to the media after receiving an H1N1 vaccine, developed by CSL of Australia, during clinical trials at the University of Iowa Health Center on August 11, 2009 in Iowa City, Iowa.
View Photo »IOWA CITY, IA - AUGUST 11: Pincipal Investiagor Dr. Pat Winokur, who is heading up clinical trials of an H1N1 vaccine developed by CSL of Australia, speaks at the University of Iowa Health Center on August 11, 2009 in Iowa City, Iowa.
View Photo »IOWA CITY, IA - AUGUST 11: Marisa Grunder, 27 of Wilton, Iowa, is given a shot during trials of an H1N1 vaccine, developed by CSL of Australia, at the University of Iowa Health Center on August 11, 2009 in Iowa City, Iowa.
View Photo »IOWA CITY, IA - AUGUST 11: Pincipal Investiagor Dr. Pat Winokur, who is heading up clinical trials of an H1N1 vaccine developed by CSL of Australia, speaks at the University of Iowa Health Center on August 11, 2009 in Iowa City, Iowa.
View Photo »IOWA CITY, IA - AUGUST 11: Marisa Grunder, 27 of Wilton, Iowa, is given a shot during trials of an H1N1 vaccine, developed by CSL of Australia, at the University of Iowa Health Center on August 11, 2009 in Iowa City, Iowa.
View Photo »IOWA CITY, IA - AUGUST 11: Marisa Grunder, 27 of Wilton, Iowa, is given a shot during trials of an H1N1 vaccine, developed by CSL of Australia, at the University of Iowa Health Center on August 11, 2009 in Iowa City, Iowa.
View Photo »Handout photo taken November 1, 2008 and received on June 19, 2009 shows a laboratory in Melbourne of the biopharmaceutical company CSL in which flu vaccine is developed through egg harvesting and virus inoculation.
View Photo »Handout photo taken November 1, 2008 and received on June 19, 2009 shows a laboratory in Melbourne of the biopharmaceutical company CSL in which flu vaccine is developed through egg harvesting and virus inoculation.
View Photo »Chen Tong (L), chief editor and executive vice president of Sina.
View Photo »Cao Guowei, CEO of Sina. Com, China's largest web portal, gestures while speaking ahead of a signing agreement with the Chinese Super League on April 1, 2009 in Beijing, where Sina signed a 3-year sponsorship contract with the Chinese Football Association Super League, commonly known as...
View Photo »Chen Tong (L), chief editor and executive vice president of Sina.
View Photo »Cao Guowei, CEO of Sina. Com, China's largest web portal, gestures while speaking ahead of a signing agreement with the Chinese Super League on April 1, 2009 in Beijing, where Sina signed a 3-year sponsorship contract with the Chinese Football Association Super League, commonly known as...
View Photo »IOWA CITY, IA - AUGUST 11: A syringe of the H1N1 vaccine, developed by CSL of Australia, is held at the University of Iowa Health Center during trial of the vaccine on August 11, 2009 in Iowa City, Iowa.
View Photo »The FDA's licensure of CSL Biotherapies' thimerosal-free monovalent pandemic H1N1 vaccine for use in children aged 6 months and older is a critically important milestone ... The U.S. Centers for Disease Control has identified young children as a priority group for pandemic H1N1 vaccine administration. C...
The FDA's licensure of CSL Biotherapies' thimerosal-free monovalent pandemic H1N1 vaccine for use in children aged 6 months and older is a critically important milestone ... The U.S. Centers for Disease Control has identified young children as a priority group for pandemic H1N1 vaccine administration. C...
How can our government, and particularly Nicola Roxon, promote their swine flu vaccination program when documented evidence by the manufacturer of the vaccine, CSL Limited, clearly indicates that in certain specific situations no testing has been carried out and they cannot confirm the safety or effecti...
The serial production BMW M3 is already weight-optimised with a whole range of measures reserved for the BMW M3 CSL in the last model – the striking carbon lightweight roof, for example.
The Government of Canada has purchased 200,000 doses of unadjuvanted H1N1 vaccine from manufacturer CSL Australia
There was definitely some rotation out of cyclical stocks today and into some defensive plays like Telstra, Foster's, Woolies and CSL. In fact, the healthcare sector was by far the best performer of the day.
In terms of H1N1 vaccine production, CSL is working as quickly and efficiently as possible to manufacture H1N1 vaccine antigen and is making good progress
The study, a collaborative project between the Murdoch Childrens Research Institute and University of Melbourne, is being sponsored by Australian pharmaceutical company CSL Limited
The FDA approval of Berinert marks an important milestone in CSL Behring's ongoing commitment to satisfying the unmet needs of patients with rare and serious disorders, such as hereditary angioedema
CSL Behring LEAD grants make a real difference in the lives of people who use our therapies
CSL Behring Canada is proud to partner with the University of British Columbia to establish this scientifically important chair ... The CBR goals align with CSL Behring's mission to develop safe and effective therapies that improve the lives of patients with rare and serious diseases, and we look forwar...
CSL is committed to providing influenza vaccine to the United States and we are now able to leverage Merck’s extensive field network in meeting that commitment and in making Afluria available to many more people in the U.S. next flu season. This is yet another milestone in our companies’ shared history ...
We cut the deficit with the front-runners after the landslide victory and Shenhua will keep fighting for the CSL championship this year
This clinical trial program is part of a larger, global effort by CSL Biotherapies, in partnership with government and regulatory bodies, to bring an Influenza A/H1N1 vaccine to market in the United States, in Australia and in select regions of the Southern Hemisphere
- IamNeeshaC
3 minutes ago
- los_cabos
22 minutes ago
- nbrownberries
29 minutes ago
@kwapt you are a natural on csl! Seriously man!
- NorthStation 40 minutes ago